Table 3.

Multivariate analysis for incomplete response to the combined therapy.

Variable		RR (95%CI)	p
Patient age	> 30-y old	3.169 (1.036–9.695)	0.043
		≤ 30-y old
Donor–patient gender	Female to male	0.394 (0.055–2.84)	0.356
		Others
Donor type	URD	2.132 (0.093–49.081)	0.636
		HRD	2.234 (0.078–63.841)	0.638
		MSD	1
Disease status at HSCT	CR2 or advanced stage	2.158 (0.452–10.297)	0.335
		CR1
ATG in conditioning regimen	No	0.579 (0.034–9.78)	0.705
		Used in conditioning regimen
Stem cell source	Bone marrow + PBSC	1.198 (0.241–5.959)	0.825
		PBSC
Grades of aGVHD occurred at onset	III–IV	0.837 (0.177–3.965)	0.822
		II
Time of the onset of aGVHD post-HSCT	≤ 15 d	1.239 (0.126–12.161)	0.854
		>15 d
SR-aGVHD at combined treatment enrollment	IV	1.745 (0.353–8.632)	0.495
		III
Grades of liver aGVHD	III–IV	5.034 (1.561–16.24)	0.007
at treatment enrollment	I–II
Grades of gut aGVHD	IV	0.312 (0.052–1.884)	0.204
at treatment enrollment	I–III
Time from aGVHD onset to combination treatment	≤14 d	0.533 (0.054–5.305)	0.592
	>14 d
CMV reactivation	Yes	4.02 (1.1–14.689)	0.035
	No